ArticleBMC cancer2026
Bioinformatics analyses reveal the role of RIPK1 in clear cell renal cell carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundReceptor interacting protein kinase 1 (RIPK1) is crucial in the regulation of apoptosis; however, its significance in clear cell renal cell carcinoma (ccRCC) is not well understood.
methodsUtilizing data collected from public databases, RIPK1 expression level was compared between ccRCC and control groups. The diagnostic capability of RIPK1 was confirmed by drawing receiver operating characteristic (ROC) curve. A nomogram was created based on the RIPK1 and primary clinical features of ccRCC patients. Finally, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was employed to confirm the expression of RIPK1, and cell experiments including colony formation, cell counting kit8 (CCK-8), cell scratch, and Transwell assays were conducted to explore the role of RIPK1.
resultsThe expression of RIPK1 was higher in ccRCC samples compared to normal samples (Fold-change = 0.24), which was confirmed in in vitro verification experiments. And the area under the ROC curve (AUC) values in the TCGA-ccRCC, GSE53757, and GSE66272 datasets were all greater than 0.7, indicating that RIPK1 had acceptable diagnostic ability for ccRCC patients. Then, clinical parameters such as stage, grade, and age may serve as independent prognostic indicators for ccRCC, and a nomogram was developed based on these clinical attributes and RIPK1. The AUC values of the nomogram at 1, 3, and 5 years were 0.904, 0.841, and 0.779, respectively, proving that it can effectively distinguish patients with different prognostic outcomes. According to the results of cell experiments, the RIPK1 overexpression (OE) group was associated with increased cell viability, proliferation, invasion, and migration capabilities compared to the control group. In contrast, these capabilities were markedly decreased in cells subsequent to RIPK1 knockdown (KD).
conclusionThe elevated expression of RIPK1 may be involved in enhancing the viability of ccRCC cells and promoting their proliferation and migration capabilities, therefore establishing a basis for clarifying the function of RIPK1 in the advancement of ccRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.